Fig. 8.

SS-31 inhibits cPLA2 through the MAPK-p38 signalling pathway. A Typical images of WB results of ERK1/2, p-ERK1/2, JNK, p-JNK, p38, p-p38, cPLA2, and p-cPLA2 expression in the injured spinal cord lesions in Sham, SCI and SCI + SS-31 groups. GAPDH was utilized as a loading control. B Quantification of the protein levels of ERK1/2, p-ERK1/2, JNK, p-JNK, p38, p-p38, cPLA2, and p-cPLA2. C Typical images of WB results of p38, p-p38, cPLA2, p-cPLA2, Caspase-1, GSDMD-N, NLRP3, ASC, p62 and LC3 expression in the injured spinal cord lesions in the SCI, SCI + SS-31, and SCI + SS-31 + AA groups. GAPDH was utilized as a loading control. D Quantification of the protein levels of p38, p-p38, cPLA2 and p-cPLA2. E Quantification of the autophagy- and pyroptosis-related protein levels in the indicated groups. F Schematic diagram showing the potential protective effect of SS-31 against SCI. The data are shown as the mean ± SEM. n = 5. *P < 0.05, **P < 0.01. ns indicates no significance